(NASDAQ: FOLD) Amicus Therapeutics's forecast annual revenue growth rate of 17.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 138.45%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.82%.
Amicus Therapeutics's revenue in 2025 is $543,141,000.On average, 4 Wall Street analysts forecast FOLD's revenue for 2025 to be $192,168,025,737, with the lowest FOLD revenue forecast at $191,003,430,756, and the highest FOLD revenue forecast at $195,317,543,841. On average, 4 Wall Street analysts forecast FOLD's revenue for 2026 to be $232,891,898,371, with the lowest FOLD revenue forecast at $228,792,721,112, and the highest FOLD revenue forecast at $243,290,111,839.
In 2027, FOLD is forecast to generate $268,696,265,605 in revenue, with the lowest revenue forecast at $263,896,853,288 and the highest revenue forecast at $272,931,548,359.